IperionX's Virginia Plant Hits 200-Tonne Mark While Losses Balloon to $66.8 Million

IperionX raised Virginia titanium powder capacity to about 200 tonnes a year at no extra equipment cost, but fiscal 2026 revenue was zero and its loss widened.

IperionX has squeezed more output from its Virginia titanium powder facility without spending an extra dollar on equipment — a rare piece of good news for a company whose financial statements still show no revenue at all.

The company disclosed midweek that operational improvements lifted nominal capacity at the site from 125 tonnes per year to roughly 200 tonnes per year. Management is targeting an annualized run rate of about 200 tonnes by the end of calendar 2026, contingent on a successful ramp-up and further fine-tuning of plant procedures. The Virginia operation also moved to continuous round-the-clock shifts, seven days a week, during fiscal 2026.

Those gains came at no additional capital cost, according to the company — a detail that matters for a business burning through cash at an accelerating pace.

A Balance Sheet That Tells the Other Story

IperionX's fiscal 2026 report, released Tuesday, laid bare the cost of building a titanium supply chain from scratch. Revenue for the full year: zero. The net loss widened to $66.8 million, up sharply from a $35.3 million shortfall in fiscal 2025. Cash and cash equivalents stood at $35.2 million as of June 30, 2026.

The math is uncomfortable. Capacity buildout, heavy research and development spending, and the operational ramp-up all consume capital before a single dollar of product revenue can be booked. At last year's burn rate, the company will need to sustain momentum on the production side — or face renewed questions about future financing.

The longer-term ambition is considerably larger: Virginia's capacity is slated to reach approximately 1,400 tonnes annually by 2027. That target underscores both the scale of the opportunity and the execution risk attached to it.

B. Riley Trims Its Target

Analysts at B. Riley Securities responded to the numbers on Wednesday by cutting their price target to $34 from $52, while keeping a Buy rating on the shares. The firm pointed to the steeper second-half loss, delayed revenue recognition, and development costs that ran above expectations.

The revision landed alongside broader pressure on the stock. Over the past twelve months, the equity has shed 66 percent of its value. Even the validation of the company's GenX-HAMR platform, reported roughly three weeks ago, failed to arrest the slide — shares have fallen 8.2 percent since that announcement. The market, it seems, is no longer willing to reward technical milestones without evidence of commercial viability.

Friday's Bounce Comes Without a Catalyst

Shares added 5.1 percent in German trading on Friday to close at EUR 1.54. Media reports cited no specific corporate trigger for the move. Set against a bruising year in which the stock has given back 51 percent since January, the gain looks more like a tentative exhale than a turning point.

What matters for IperionX now is whether the 200-tonne annualized rate materializes on schedule — and whether it marks the shift from development-stage hopeful to commercially viable supplier. Strategic demand for an independent Western titanium source is not in question; titanium remains essential to aerospace, defense, and advanced manufacturing, and its traditional processing is both energy-intensive and costly. But strategic tailwinds do not substitute for margins or revenue.

Until the ramp-up proves stable and contracted offtake follows, the stock remains a volatile barometer for the risks of industrial pioneering.